Fresenius is reportedly planning to back off from efforts to acquire the medical nutrition unit of France’s Danone because the process is taking too long, say reports.
According to unnamed sources, the German medical conglomerate is slated to abandon the bidding race for Danone, though one source said it was too early to definitely say that Fresenius has taken the decision to walk away. Another source told reporters that Danone had repeatedly missed deadlines in the companies’ merger discussions.
Reports say the Danone acquisition could be worth up to $6 billion.
Danone has been looking to divest its medical nutrition assets to fund its pursuit of top US infant formula maker Mead Johnson Nutrition, sources say.
Full content: Reuters
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Hess Shareholders Approve $53 Billion Merger with Chevron
May 28, 2024 by
CPI
EU Regulators Engage with Telegram as App Nears Critical Usage Threshold
May 28, 2024 by
CPI
EEX Offers Remedies to Address EU Antitrust Concerns Over Nasdaq Deal
May 28, 2024 by
CPI
BRG Expands European Competition Practice with New Expert Team in Brussels
May 28, 2024 by
CPI
UK Law Empowers Regulators to Fine Big Tech Without Court Approval
May 28, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Merger Guidelines Retrospective
May 21, 2024 by
CPI
Mergers of Complements
May 21, 2024 by
CPI
Personality Traits, Private Equity, and Merger Analysis
May 21, 2024 by
CPI
The 2023 Merger Guidelines: Lessons in the Importance of Incipiency, Modern Economics, and Monopsony
May 21, 2024 by
CPI
The 2023 Merger Guidelines: Sharpening Merger Analysis
May 21, 2024 by
CPI